Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer

References

• Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J General Physiol 1927; 8:519-30
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70; PMID:10647931
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324:1029-33; PMID:19460998
   PubMed Web of Science ®Google Scholar
• Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 0000; 25:4633-46
   Google Scholar
• Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer 2013; 12:152; PMID:24298908
   PubMed Web of Science ®Google Scholar
• Gu L, Xie L, Zuo C, Ma Z, Zhang Y, Zhu Y, Gao J. Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma. BMC Cancer 2015; 15:529
   PubMed Web of Science ®Google Scholar
• Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, Shi XB, deVere White RW, Gao AC. Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate 2013; 73:418-27; PMID:22996738
   PubMed Web of Science ®Google Scholar
• Serrano MA, Li Z, Dangeti M, Musich PR, Patrick S, Roginskaya M, Cartwright B, Zou Y. DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair. Oncogene 2013; 32:2452-62; PMID:22797063
   PubMed Web of Science ®Google Scholar
• Gogna R, Madan E, Kuppusamy P, Pati U. Chaperoning of mutant p53 protein by wild-type p53 protein causes hypoxic tumor regression. J Biol Chem 2012; 287:2907-14; PMID:22147694
   PubMed Web of Science ®Google Scholar
• Puzio-Kuter AM. The Role of p53 in Metabolic Regulation. Genes Cancer 2011; 2:385-91; PMID:21779507
   PubMedGoogle Scholar
• Kruiswijk F, Labuschagne CF, Vousden KH. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol 2015; 16:393-405; PMID:26122615
   PubMed Web of Science ®Google Scholar
• Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126:107-20; PMID:16839880
   PubMed Web of Science ®Google Scholar
• Bensaad K, Cheung EC, Vousden KH. Modulation of intracellular ROS levels by TIGAR controls autophagy. Embo J 2009; 28:3015-26; PMID:19713938
   PubMed Web of Science ®Google Scholar
• Kim HR, Roe JS, Lee JE, Cho EJ, Youn HD. p53 regulates glucose metabolism by miR-34a. Biochem Biophy Res Commun 2013; 437:225-31
   PubMed Web of Science ®Google Scholar
• Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutation 2007; 28:622-9
   PubMed Web of Science ®Google Scholar
• Lowe SW. Activation of p53 by oncogenes. Endocrine-Related Cancer 1999; 6:45-8; PMID:10732786
   PubMed Web of Science ®Google Scholar
• Box NF, Vukmer TO, Terzian T. Targeting p53 in melanoma. Pigment Cell Melanoma Res 2014; 27:8-10; PMID:24118922
   PubMed Web of Science ®Google Scholar
• van Oijen MG, Slootweg PJ. Gain-of-Function Mutations in the Tumor Suppressor Gene p53. Clin Cancer Res 2000; 6:2138-45; PMID:10873062
   PubMed Web of Science ®Google Scholar
• Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev 2012; 26:1268-86; PMID:22713868
   PubMed Web of Science ®Google Scholar
• Griewe GL, Dean RC, Zhang W, Young D, Sesterhenn IA, Shanmugam N, McLeod DG, Moul JW, Srivastava S. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein. Prostate Cancer Prostatic Dis 0000; 6:281-5
   Google Scholar
• Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell Death Differentiation 2006; 13:941-50; PMID:16601750
   PubMed Web of Science ®Google Scholar
• Kapetanovic IM, Muzzio M, McCormick DL, Thompson TN, Johnson WD, Horn TL, Mohammed A, Rao CV, Kopelovich L. Pharmacokinetics and tissue and tumor exposure of CP-31398, a p53-stabilizing agent, in rats. Cancer Chemotherapy Pharmacol 2012; 69:1301-6; PMID:22302406
   PubMed Web of Science ®Google Scholar
• Mouraret N, Marcos E, Abid S, Gary-Bobo G, Saker M, Houssaini A, Dubois-Rande JL, Boyer L, Boczkowski J, Derumeaux G, et al. Activation of Lung p53 by Nutlin-3a Prevents and Reverses Experimental Pulmonary Hypertension. Circulation 2013; 127:1664-76; PMID:23513067
   PubMed Web of Science ®Google Scholar
• Sakaguchi K, Herrera JE, Saito Si, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E. DNA damage activates p53 through a phosphorylation–acetylation cascade. Genes Dev 1998; 12:2831-41; PMID:9744860
   PubMed Web of Science ®Google Scholar
• Liu Y, Kulesz-Martin M. p53 protein at the hub of cellular DNA damage response pathways through sequence-specific and non-sequence-specific DNA binding. Carcinogenesis 2001; 22:851-60; PMID:11375889
   PubMed Web of Science ®Google Scholar
• Meek DW. The p53 response to DNA damage. DNA Repair 2004; 3:1049-56; PMID:15279792
   PubMed Web of Science ®Google Scholar
• Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation Is Indispensable for p53 Activation. Cell; 133:612-26; PMID:18485870
   PubMed Web of Science ®Google Scholar
• Brooks C, Gu W. The impact of acetylation and deacetylation on the p53 pathway. Protein Cell 2011; 2:456-62; PMID:21748595
   PubMed Web of Science ®Google Scholar
• Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, McCarthy A, Appleyard V, Murray KE, Baker L, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008; 13:454-63; PMID:18455128
   PubMed Web of Science ®Google Scholar
• Liu XS, Li H, Song B, Liu X. Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery. EMBO Reports 2010; 11:626-32; PMID:20577264; http://dx.doi.org/10.1038/embor.2010.90
   PubMed Web of Science ®Google Scholar
• Yang X, Li H, Zhou Z, Wang WH, Deng A, Andrisani O, Liu X. Plk1-mediated phosphorylation of Topors regulates p53 stability. J Biol Chem 2009; 284:18588-92; PMID:19473992; http://dx.doi.org/10.1074/jbc.C109.001560
   PubMed Web of Science ®Google Scholar
• Dias SS, Hogan C, Ochocka AM, Meek DW. Polo-like kinase-1 phosphorylates MDM2 at Ser260 and stimulates MDM2-mediated p53 turnover. FEBS Letters 2009; 583:3543-8; PMID:19833129; http://dx.doi.org/10.1016/j.febslet.2009.09.057
   PubMed Web of Science ®Google Scholar
• Sanhaji M, Louwen F, Zimmer B, Kreis N-N, Roth S, Yuan J. Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53. Cell Cycle 2013; 12:1340-51; PMID:23574746; http://dx.doi.org/10.4161/cc.24573
   PubMed Web of Science ®Google Scholar
• Lansing TJ, McConnell RT, Duckett DR, Spehar GM, Knick VB, Hassler DF, Noro N, Furuta M, Emmitte KA, Gilmer TM, et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol Cancer Therapeutics 2007; 6:450-9; PMID:17267659; http://dx.doi.org/10.1158/1535-7163.MCT-06-0543
   PubMed Web of Science ®Google Scholar
• Li Z, Li J, Bi P, Lu Y, Burcham G, Elzey BD, Ratliff T, Konieczny SF, Ahmad N, Kuang S, et al. Plk1 Phosphorylation of PTEN Causes a Tumor-Promoting Metabolic State. Mol Cell Biol 2014; 34(19):3642-61
   PubMed Web of Science ®Google Scholar
• Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. Annals Translational Med 2014; 2:57; PMID:25333032
   PubMedGoogle Scholar
• Andrzejewski S, Gravel SP, Pollak M, St-Pierre J. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab 2014; 2:12; PMID:25184038; http://dx.doi.org/10.1186/2049-3002-2-12
   PubMedGoogle Scholar
• Vujic I, Sanlorenzo M, Posch C, Esteve-Puig R, Yen AJ, Kwong A, Tsumura A, Murphy R, Rappersberger K, Ortiz-Urda S. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget 2015; 6:969-78; PMID:25504439; http://dx.doi.org/10.18632/oncotarget.2824
   PubMed Web of Science ®Google Scholar
• Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget 2011; 2:222-33; PMID:21447859; http://dx.doi.org/10.18632/oncotarget.248
   PubMed Web of Science ®Google Scholar
• Shao C, Ahmad N, Hodges K, Kuang S, Ratliff T, Liu X. Inhibition of Polo-like Kinase 1 (Plk1) Enhances the Antineoplastic Activity of Metformin in Prostate Cancer. J Biol Chem 2015; 290:2024-33; PMID:25505174; http://dx.doi.org/10.1074/jbc.M114.596817
   PubMed Web of Science ®Google Scholar
• McKenzie L, King S, Marcar L, Nicol S, Dias SS, Schumm K, Robertson P, Bourdon JC, Perkins N, Fuller-Pace F, et al. P53-dependent repression of polo-like kinase-1 (PLK1). Cell Cycle 2010; 9:4200-12; PMID:20962589; http://dx.doi.org/10.4161/cc.9.20.13532
   PubMed Web of Science ®Google Scholar
• Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S, Fukuzawa M, Nakagawara A. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 2004; 279:25549-61; PMID:15024021; http://dx.doi.org/10.1074/jbc.M314182200
   PubMed Web of Science ®Google Scholar